Oncotelic’s AI Platform Opens Collaboration Portal, Showcases Drug Discovery Breakthrough

  • Oncotelic’s PDAOAI platform launched BIO REBOOT collaboration initiative on October 5, 2026, inviting scientists and developers to participate in drug discovery projects.
  • The platform demonstrated its Partitioned Literature Aggregation (PLA) method at Drug Discovery 2026, identifying a four-gene signature for hepatocellular carcinoma.
  • Selected projects through BIO REBOOT may receive startup funding and development support from Oncotelic.
  • PDAOAI currently indexes 29 million PubMed abstracts, using AI to uncover relationships across genes, pathways, and diseases.

Oncotelic’s move to open its AI platform to external collaborators reflects the growing trend of biotech firms leveraging crowdsourced innovation to accelerate drug discovery. The company’s ability to demonstrate tangible research outputs, like the hepatocellular carcinoma case study, positions it competitively in a market increasingly dominated by AI-driven insights. Success will depend on converting early interest into sustainable partnerships and funding commitments.

Platform Adoption
How quickly BIO REBOOT attracts high-quality collaborators and whether the platform can sustain momentum beyond initial interest.
Commercialization Pace
The speed at which PDAOAI-generated hypotheses translate into funded projects and clinical development.
Competitive Differentiation
Whether Oncotelic can maintain a technological edge as larger players like Amgen and Eli Lilly integrate similar AI tools.